Tirzepatide (Mounjaro) for Type 2 Diabetes
Tirzepatide (Mounjaro) for Type 2 Diabetes
July 11, 2022 (Issue: 1654)
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2...more
- Drugs for type 2 diabetes. Med Lett Drugs Ther 2019; 61:169.
- Semaglutide (Wegovy) for weight loss. Med Lett Drugs Ther 2021; 63:106.
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- J Rosenstock et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021; 398:143.
- JP Frias et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385:503.
- B Ludvik et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021; 398:583.
- S Del Prato et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021; 398:1811.
- D Dahl et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022; 327:534.
- N Sattar et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022; 28:591.
- AM Jastreboff et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med June 4, 2022 (epub).
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Tirzepatide (Mounjaro) for Type 2 Diabetes
Article code: 1654a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
